Drug Discovery World

FEBRUARY 15, 2024

Mark Treherne will talk about advanced therapies and the development of RNA gene therapy for aggressive cancers which is being carried out at Spliceor.

Therapies 130

Therapies RNA Science Marketing 130

Drug Discovery World

FEBRUARY 5, 2024

Doug Danison will discuss transitioning innovative science into commercial success in the areas of CGTs. Mark Treherne will talk about advanced therapies and the development of RNA gene therapy for aggressive cancers which is being carried out at Spliceor.

Therapies 130

Therapies Marketing RNA Science 130

Drug Discovery World

FEBRUARY 22, 2024

Doug Danison will discuss transitioning innovative science into commercial success in the areas of CGTs. Mark Treherne will talk about advanced therapies and the development of RNA gene therapy for aggressive cancers which is being carried out at Spliceor.

Therapies 130

Therapies RNA Science Marketing 130

Drug Discovery World

FEBRUARY 13, 2024

In this webinar, hosted by DDW and sponsored by Astrea Bioseparations, you will learn about how market growth can be sustained to maximise on opportunities in cell and gene therapy (CGT). Doug Danison will discuss transitioning innovative science into commercial success in the areas of CGTs.

Therapies 130

Therapies Marketing RNA Science 130

Drug Target Review

DECEMBER 6, 2023

Dear readers, RNA, or ribonucleic acid, plays a pivotal role in the intricate dance of cellular processes. We are committed to providing you with the highest quality content, and we believe that this report will deliver a different perspective on the topics covered.

RNA 52

RNA DNA Vaccine Science 52

Drug Discovery World

AUGUST 7, 2024

The grant will fund a collaboration that combines scientific expertise with machine vision tools with an aim to streamline the synthesis, purification and analysis of RNA medicines. Sam Whitmarsh, Director of Analytical Science and Digital Transformation at CatSci, commented: “I’m thrilled that we have won the Innovate UK grant.

RNA 147

RNA Government Therapies Science 147

Drug Target Review

AUGUST 28, 2024

Once a patient develops advanced cirrhosis/end-stage liver disease there are no specific therapies to significantly avoid major decompensations and death in the next few years. Could you describe the platform of macrophage biology and cell engineering used by Resolution Therapeutics in developing their cell therapies?

Therapies 114

Therapies Disease Engineering Medical Schools 114

Drug Discovery World

MARCH 6, 2023

The post Institiute gives a boost to five new life science start-ups appeared first on Drug Discovery World (DDW). In total, BII’s start-ups have raised over €333 million in external funding from both local and international investors.

Science 130

Science RNA Disease International 130

Drug Target Review

JUNE 15, 2023

In this article Drug Target Review’s Izzy Wood spoke to Sam Hasson, Director of Target Biology at Rgenta Therapeutics, a biotech firm in Massachusetts, US, that aims to develop small molecule therapeutics to target RNA processing. The field is faced with a number of obstacles that require specifically assay technologies to surmount.

RNA 96

RNA Small Molecule Disease Assay Development 96

BioPharma Drive: Drug Pricing

JUNE 3, 2024

With new modalities such as gene and cell therapies, RNA therapeutics, complex biologics and more, today’s science brings unprecedented opportunities to address diseases that have long remained out of reach.

Science 57

Science RNA Therapies Disease 57

Drug Discovery World

AUGUST 30, 2024

The investment from Innovate UK will drive both early and later stage innovations in cancer therapies, building on UK economic potential in this field. The companies participated in Innovate UK’s Oncology Accelerator, delivered by Lean Life Science in 2023 and co-funded by Cancer Research Horizons.

DNA 147

DNA Drugs RNA Therapies 147

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. million price point per dose.

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

Drug Discovery World

JANUARY 17, 2023

Oregon State University College of Pharmacy scientists have shown that lipid nanoparticles and messenger RNA could treat blindness associated with a rare genetic condition. . Limitations of AAV gene therapy . We identified a novel set of peptides that can reach the back of the eye,” Sahay said. “The

Small Molecule 246

Small Molecule Pharmacy RNA Packaging 246

Drug Discovery World

MAY 22, 2023

Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report. Pharma is also keen to access next generation RNA platforms, such as self-amplifying RNAs derived from the genomes of positive-strand RNA viruses.

Pharma Companies 130

Pharma Companies RNA Therapies Virus 130

Drug Discovery World

JANUARY 9, 2024

Italy-based Resalis Therapeutics has closed a €10 million ($11 million) Series A financing round led by Sunstone Life Science Ventures with participation from existing investors. With RES-010 we aim to provide a therapeutic that precisely reduces fat mass in obesity with the potential to extend the durability of existing therapies.

Disease 130

Disease Drugs RNA Clinical Trials 130

Drug Discovery World

OCTOBER 24, 2022

New research suggests messenger RNA can be effectively used as a ‘universal’ therapy against different coronaviruses. . Rather than messenger RNA as a vaccine, this shows that mRNA can be used as a universal therapy against different coronaviruses,” said Gaurav Sahay, OSU and the Texas Biomedical Research Institute.

Treatment 100

Treatment RNA Protein Production Virus 100

Drug Discovery World

JANUARY 23, 2024

Professor Anubhav Tripathi One of the featured speakers, Anubhav Tripathi, Professor of Medical Science and Engineering at Brown University, will address the topic ‘ Accelerating biotherapeutics development through technology platforms ’ on Tuesday 6 February at 3.30pm.

Drug Development 130

Drug Development RNA Drugs Engineering 130

Drug Discovery World

OCTOBER 5, 2023

Join DDW’s Megan Thomas and Reece Armstrong with sponsors Taconic for the first DDW Turning Science into Business Summit, ‘ Cancer research opportunities and advances ’, on 16 November at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. Find out the answer to questions such as: Where is the opportunity in the cancer research market?

Research 130

Research RNA Vaccine Science 130

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. billion in funding.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

Drug Discovery World

JULY 2, 2024

DDW’s Diana Spencer takes a closer look into why Switzerland is such a life sciences powerhouse and how Swiss researchers are advancing new technology and tackling modern health challenges. Switzerland, however, boasts three (or arguably, four) separate yet complimentary centres of life science innovation.

Science 147

Science Drugs Clinical Trials Licensing 147

Drug Discovery World

SEPTEMBER 21, 2023

A new research paper published in Science illustrates how neurons initiate a programmed form of cell death, known as necroptosis, when they are exposed to amyloid plaques and tau tangles.

Disease 263

Disease RNA Research Science 263

Drug Discovery World

AUGUST 9, 2023

The life sciences sector has seen significant M&A activity over the last few weeks. Read more: Théa acquires ProQR’s RNA ophthalmic assets Sygnature Discovery acquires NuChem Sciences Sygnature Discovery acquired Canada-based contract research organisation NuChem Sciences, expanding its business operations into the North American market.

FDA Approval 130

FDA Approval Drugs Science RNA 130

Science Daily: Pharmacology News

MAY 29, 2024

Functional analysis based on these structures also revealed how a 'prime editor' could achieve reverse transcription, synthesizing DNA from RNA, without 'cutting' both strands of the double helix. Clarifying these molecular mechanisms contributes greatly to designing gene-editing tools accurate enough for gene therapy treatments.

RNA 97

RNA DNA Therapies Treatment 97

Drug Discovery World

OCTOBER 11, 2023

The DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances ’ will feature an expert panel discussion on new drug discovery and development concepts and tools in cancer research. The free two-hour Summit, hosted by DDW, will take place online on 16 November at 7AM PDT / 10AM EDT / 3PM GMT / 4PM CET.

Research 130

Research Molecular Biology RNA Engineering 130

Drug Discovery World

JULY 15, 2024

Key takeaways The mission of the AACR is to prevent and cure cancer through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research. This bodes well for potential future research and therapies,” she adds.

Research 130

Research Clinical Pharmacology Therapies RNA 130

Drug Discovery World

MARCH 13, 2024

With government support and strong academic institutions, does Singapore have what it takes to become a global centre for life sciences? DDW’s Diana Spencer explores how the country is turning pioneering science into a successful biotech industry. UK-based molecular diagnostics group Yourgene operates in Singapore.

Government 173

Government Science Pharmaceuticals Vaccine 173

Alta Sciences

MARCH 1, 2024

Norbert Makori and Pierre Jolicoeur: The Benefits of Combining Preclinical and Bioanalytical for Your Gene Therapy Studies pmjackson Fri, 03/01/2024 - 22:20 Recent advances in gene therapy have allowed for diseases to be approached differently. q: How can Altasciences support sponsors’ Gene Therapy Programs?

Therapies 52

Therapies Laboratories Molecular Biology RNA 52

Drug Discovery World

APRIL 11, 2023

The molecule, known as lissodendoric acid A, appears to counteract other molecules that can damage DNA, RNA and proteins and even destroy whole cells. Dysregulation of mitophagy is closely linked to the development of several diseases, with USP30 modulation offering a potential treatment.

Drug Research 130

Drug Research Research Drugs RNA 130

Broad Institute

JUNE 28, 2023

Today, scientists use these reactions to produce customizable DNA and RNA molecules that enable genetic sequencing, drug and vaccine development, pathogen tests, cancer diagnostics, and many aspects of basic biomedical research. “I Longer synthetic DNA and RNA molecules are also critical for modern biologic drugs.

DNA 98

DNA RNA Science Therapies 98

The Pharma Data

SEPTEMBER 28, 2020

This included compiling RNA data, as well as other data points such as patient demographics, clinical treatment arm and patient diagnosis. However, for others, it did not work – or did so only marginally, or with serious side effects,” said Stuart Henderson, global Life Sciences lead for Accenture.

Science 52

Science Clinical Trials RNA Treatment 52

Drug Discovery World

JULY 8, 2024

Beard Distinguished Professor of Experimental Surgery and the Founding Director of the Translational Research Institute at Duke University, explores the rise of RNA therapeutics. However, the RNA landscape has drastically changed in recent years and we now know that the molecule is more than just a transient, linear carrier of information.

RNA 147

RNA Small Molecule Vaccine FDA Approval 147

Science Daily: Pharmacology News

JULY 27, 2023

If translated into the clinic, this approach could expand access and reduce the cost of gene therapies for blood disorders, many of which currently require patients receive chemotherapy and a stem cell transplant.

RNA 55

RNA Research Therapies Disease 55

Broad Institute

AUGUST 19, 2024

I’m so proud of this team and the partnership we formed to follow the science and set up some major positive impacts on women’s health,” Blainey said. Using RNA sequencing and working with the Broad’s Metabolomics Platform and collaborators at St. Paper cited Zhu M et al.

Hospitals 121

Hospitals Medical Schools Treatment Science 121

Drug Discovery World

APRIL 27, 2023

The first quarter of 2023 has seen deal flow continue for UK life science and biotech companies at all stages of development, new data from the UK BioIndustry Association and Clarivate shows. million to advance its gene therapy platform to treat cancer. million across 20 deals, with an average deal size of £13 ($16.1)

RNA 130

RNA Science Marketing Treatment 130

The Pharma Data

MARCH 9, 2022

Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene therapies for neurological diseases, with options to access capsids for two other targets. About Novartis.

Licensing 52

Licensing Licensing Therapies Disease 52

Drug Target Review

APRIL 26, 2023

Scientists from the Massachusetts Institute of Technology (MIT) and the University of Massachusetts Medical School (UMass), US, have collaborated to create a novel type of nanoparticle that can deliver messenger RNA that encodes for beneficial proteins to the lungs. The study appears in Nature Biotechnology.

RNA 98

RNA Medical Schools Engineering DNA 98

Drug Discovery World

APRIL 30, 2024

Reece Armstrong explores the potential and future opportunities for mRNA-based therapies. Messenger RNA (mRNA) has come into focus within the drug discovery and development as an exciting tool to deliver genetic information. For instance, consider how at the end of 2018, the mRNA therapies market was valued at $3.43

Therapies 130

Therapies RNA Vaccine Small Molecule 130